Healthcare Today

Healthcare Today In-depth information on medical/health/ and wellness practices in Malaysia. https://ghpnews.digital/winners/na-healthcaretoday-ventures/

Winner of Medical News Platform of the Year 2025 APAC(UK) &GHP (UK) Leading Healthcare News Platform 2024 - Malaysia.

MY-IVL Real-World study demonstrates 96.1% freedom from major adverse cardiovascular eventshttp://healthcaretoday.com.my...
30/01/2026

MY-IVL Real-World study demonstrates 96.1% freedom from major adverse cardiovascular events

http://healthcaretoday.com.my/new-mechanical-intravascular-lithotripsy-system-emerges-as-interventional-cardiologists-preferred-choice.html

CVSKL - Cardiac Vascular Sentral Kuala Lumpur

The LithiX Hertz Contact (HC) Intravascular Lithotripsy system, a novel mechanical lithotripsy system, is quickly becoming the preferred calcium-modification tool for severely calcified coronary artery disease (CAD) in leading hospitals across Malaysia.

TibaRay advances FLASH radiotherapy, delivering ultra-fast, precise treatment for improved outcomeshttp://healthcaretoda...
29/01/2026

TibaRay advances FLASH radiotherapy, delivering ultra-fast, precise treatment for improved outcomes

http://healthcaretoday.com.my/ihh-healthcare-invests-in-tibaray-to-transform-cancer-care-with-precision-radiotherapy.html

IHH Healthcare

IHH Healthcare has made a strategic investment in TibaRay, a US based medical technology company developing next-generation radiation therapy. The investment reinforces the group’s commitment to clinical excellence, patient safety, and transformative adva

Retirement is often misunderstood as the final chapter of life — a time to slow down, step aside, and quietly fade into ...
27/01/2026

Retirement is often misunderstood as the final chapter of life — a time to slow down, step aside, and quietly fade into the background. But what if retirement is not an ending at all?

In this video, Tan Sri Lee Lam Thye, Chairman and Founder of the Alliance for a Safe Community, challenges the outdated idea of retirement during his keynote address at the Supporting Mental Well-being Together: Rewirement, Not Retirement conference. He reminds us that retirement should not mean retiring from life, but rather rewiring it.

With longer life expectancy and richer life experience, today’s seniors have the opportunity to redefine purpose, dignity and contribution beyond the age of 60. From lifelong learning and volunteerism to entrepreneurship, community engagement and staying physically active, retirement can be a powerful season of renewal and meaning.

This video explores how seniors can remain relevant, valued and fulfilled — not by earning more, but by making their years count. It is a message of hope, empowerment and renewed purpose for retirees, families and society as a whole.

Because retirement is not a retreat.
It is a new beginning.

👉 Watch, reflect, and be inspired to reimagine life after retirement.

https://youtu.be/slKUyQF0oA4

Retirement is often misunderstood as the final chapter of life — a time to slow down, step aside, and quietly fade into the background. But what if retiremen...

When it comes to weight loss, the problem isn’t your stomach — it’s your brain.In part 2 of this talk, Professor Emeritu...
20/01/2026

When it comes to weight loss, the problem isn’t your stomach — it’s your brain.

In part 2 of this talk, Professor Emeritus Professor Dr Chan Siew Pheng explains why eating behavior is regulated by multiple centers in the brain, not willpower alone. She breaks down the science behind homeostatic eating (eating in response to true hunger for survival), hedonic eating (eating for pleasure), and the brain’s self-regulation system that influences decision-making around food.

The challenge begins when weight loss triggers the body’s natural defense mechanisms. As people eat less and move more, they may initially lose weight — but the body responds by slowing metabolism, increasing hunger, and reducing feelings of fullness. In effect, the body actively works to regain lost weight, which explains why many people experience frustration and repeated cycles of weight regain.

Professor Dr Chan outlines how modern clinical guidelines approach obesity as a chronic disease, emphasizing that medications must always be used alongside lifestyle changes such as diet and physical activity. Treatment is not a shortcut, but a medical tool to support long-term health.

The talk also explores the role of high-dose semaglutide, explaining how it differs from lower-dose formulations and why it carries strong clinical trial evidence. Studies show significant, sustained weight loss — in some cases comparable to bariatric surgery — without the need for invasive procedures.

Importantly, clinical trials demonstrate that this treatment leads to greater fat loss with less muscle loss, addressing concerns about weakness and functional decline. Reductions in visceral fat, particularly around the abdomen, translate into meaningful improvements in blood sugar, cholesterol levels, and cardiovascular risk.

Beyond the scale, Professor Dr Chan highlights how weight management today is measured by health outcomes, not just pounds or kilograms lost. Large clinical trials, including cardiovascular outcome studies, show reduced risks of heart attacks, strokes, and cardiovascular death — even in patients without diabetes.

This session offers a science-based perspective on why weight loss is so difficult, how the body resists change, and how modern obesity care is evolving toward compassionate, evidence-driven treatment.

https://youtu.be/XkROuplsjPY

When it comes to weight loss, the problem isn’t your stomach — it’s your brain.In part 2 of this talk, Professor Emeritus Professor Dr Chan Siew Pheng explai...

Obesity is not a personal failure — it is a chronic disease shaped by biology, environment, and physiology. In this publ...
20/01/2026

Obesity is not a personal failure — it is a chronic disease shaped by biology, environment, and physiology. In this public talk, Professor Emeritus Professor Dr Chan Siew Pheng, Honorary Consultant Endocrinologist, explains why obesity should be approached with science and compassion, not stigma.

She introduces the respectful term People With Obesity (PWO) and highlights Malaysia’s growing health challenge, where many individuals live with the “3 plus 1” combination of diabetes, hypertension, high cholesterol, and obesity — all in the same person.

Drawing from Ministry of Health data, Professor Dr Chan outlines how rates of overweight and obesity in Malaysia have risen from 40% to over 50% in just over a decade. She explains how obesity is diagnosed using BMI and waist circumference, and why Asian populations require lower BMI cut-off points due to higher risks of diabetes and cardiovascular disease at lower body weights.

The talk also explores findings from the ACTION Malaysia study, revealing widespread awareness of obesity’s health impact — yet persistent blame, stigma, and lack of effective treatment. Many people regain lost weight due to biological defence mechanisms that slow metabolism, increase hunger, and drive cravings.

Professor Dr Chan explains how eating behavior is regulated by the brain through homeostatic eating (hunger), hedonic eating (pleasure), and self-regulation — and why the body actively fights weight loss, leading to frustration and yo-yo dieting.

This session offers a clear, evidence-based perspective on obesity as a medical condition, not a character flaw, and why long-term management requires understanding biology, not just willpower.

https://youtu.be/hIO0bz21vm8

Obesity is not a personal failure — it is a chronic disease shaped by biology, environment, and physiology. In this public talk, Professor Emeritus Professor...

Wegovy (semaglutide 2.4 mg) is a once-weekly injectable GLP-1 receptor agonist that works by mimicking the natural hormo...
16/01/2026

Wegovy (semaglutide 2.4 mg) is a once-weekly injectable GLP-1 receptor agonist that works by mimicking the natural hormone GLP-1 released by the gut after eating. This mechanism targets specific areas of the brain involved in appetite regulation, helping to reduce hunger, cravings, and what many patients describe as persistent “food noise.”

http://healthcaretoday.com.my/novo-nordisk-launches-wegovy-to-combat-obesity-and-cardiovascular-risk.html

Wegovy (semaglutide 2.4 mg) is a once-weekly injectable GLP-1 receptor agonist that works by mimicking the natural hormone GLP-1 released by the gut after eating. This mechanism targets specific areas of the brain involved in appetite regulation, helping

Address

Kuala Lumpur

Alerts

Be the first to know and let us send you an email when Healthcare Today posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram